Olmesartan
Olmesartan structure
|
Common Name | Olmesartan | ||
|---|---|---|---|---|
| CAS Number | 144689-24-7 | Molecular Weight | 446.502 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 738.3±70.0 °C at 760 mmHg | |
| Molecular Formula | C24H26N6O3 | Melting Point | 186-188ºC | |
| MSDS | Chinese USA | Flash Point | 400.3±35.7 °C | |
|
Structure-response relationship in electrospray ionization-mass spectrometry of sartans by artificial neural networks.
J. Chromatogr. A. 1438 , 123-32, (2016) Quantitative structure-property relationship (QSPR) methods are based on the hypothesis that changes in the molecular structure are reflected in changes in the observed property of the molecule. Artificial neural network is a technique of data analysis, which... |
|
|
Synergistic, cytotoxic and apoptotic activities of olmesartan with NF-κB inhibitor against HeLa human cell line.
Toxicol. Mech. Methods 25 , 614-21, (2015) Over expression of renin-angiotensin system (RAS) and nuclear factor-kappaB (NF-κB) has a major role in many cancers. It has been suggested that some angiotensin receptor blockers (ARBs) could reduce the proliferation of cancer cells. The role of NF-κB pathwa... |
|
|
Linear mixed-effects model of QTc prolongation for olmesartan medoxomil.
J. Clin. Pharmacol. , doi:10.1002/jcph.572, (2015)
|
|
|
Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses.
PLoS Med. 13 , e1001971, (2016) Medications aimed at inhibiting the renin-angiotensin system (RAS) have been used extensively for preventing cardiovascular and renal complications in patients with diabetes, but data that compare their clinical effectiveness are limited. We aimed to compare ... |